IL233886A - Solid anhydrous crystalline form of 6 - (2 - ((4-amino-3- (3-hydroxyphenyl) -1h- pyrazolo [3,4- d] pyrimidine-1-yl) methyl) -3- (2-chlorobenzyl) -4-oxo-3,4 dihydroquinazoline-5-yl) n, n-bis (2-methoxyethyl) hex-5-inamide - Google Patents

Solid anhydrous crystalline form of 6 - (2 - ((4-amino-3- (3-hydroxyphenyl) -1h- pyrazolo [3,4- d] pyrimidine-1-yl) methyl) -3- (2-chlorobenzyl) -4-oxo-3,4 dihydroquinazoline-5-yl) n, n-bis (2-methoxyethyl) hex-5-inamide

Info

Publication number
IL233886A
IL233886A IL233886A IL23388614A IL233886A IL 233886 A IL233886 A IL 233886A IL 233886 A IL233886 A IL 233886A IL 23388614 A IL23388614 A IL 23388614A IL 233886 A IL233886 A IL 233886A
Authority
IL
Israel
Prior art keywords
ynamide
dihydroquinazolin
pyrazolo
chlorobenzyl
pyrimidin
Prior art date
Application number
IL233886A
Other languages
English (en)
Hebrew (he)
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49160309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL233886(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of IL233886A publication Critical patent/IL233886A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL233886A 2012-03-13 2014-07-30 Solid anhydrous crystalline form of 6 - (2 - ((4-amino-3- (3-hydroxyphenyl) -1h- pyrazolo [3,4- d] pyrimidine-1-yl) methyl) -3- (2-chlorobenzyl) -4-oxo-3,4 dihydroquinazoline-5-yl) n, n-bis (2-methoxyethyl) hex-5-inamide IL233886A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610023P 2012-03-13 2012-03-13
US201261610012P 2012-03-13 2012-03-13
PCT/GB2013/050624 WO2013136076A1 (en) 2012-03-13 2013-03-13 Crystalline pi3 kinase inhibitors

Publications (1)

Publication Number Publication Date
IL233886A true IL233886A (en) 2017-12-31

Family

ID=49160309

Family Applications (2)

Application Number Title Priority Date Filing Date
IL233886A IL233886A (en) 2012-03-13 2014-07-30 Solid anhydrous crystalline form of 6 - (2 - ((4-amino-3- (3-hydroxyphenyl) -1h- pyrazolo [3,4- d] pyrimidine-1-yl) methyl) -3- (2-chlorobenzyl) -4-oxo-3,4 dihydroquinazoline-5-yl) n, n-bis (2-methoxyethyl) hex-5-inamide
IL233883A IL233883A0 (en) 2012-03-13 2014-07-30 New pharmaceutical formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL233883A IL233883A0 (en) 2012-03-13 2014-07-30 New pharmaceutical formulations

Country Status (35)

Country Link
US (3) US9642799B2 (enExample)
EP (2) EP2834244B1 (enExample)
JP (3) JP2015509973A (enExample)
KR (2) KR20140131971A (enExample)
CN (2) CN104284679B (enExample)
AU (2) AU2013234081B2 (enExample)
CA (2) CA2864643A1 (enExample)
CL (2) CL2014002386A1 (enExample)
CO (2) CO7061079A2 (enExample)
CR (2) CR20140416A (enExample)
CY (1) CY1118565T1 (enExample)
DK (1) DK2834244T3 (enExample)
EA (2) EA025465B1 (enExample)
EC (2) ECSP14018142A (enExample)
ES (2) ES2650791T3 (enExample)
GT (2) GT201400182A (enExample)
HR (1) HRP20161383T1 (enExample)
HU (1) HUE029420T2 (enExample)
IL (2) IL233886A (enExample)
IN (2) IN2014MN02000A (enExample)
LT (1) LT2834244T (enExample)
MX (2) MX357170B (enExample)
MY (1) MY171125A (enExample)
NI (2) NI201400101A (enExample)
NZ (2) NZ628072A (enExample)
PE (2) PE20141964A1 (enExample)
PH (2) PH12014501713A1 (enExample)
PL (1) PL2834244T3 (enExample)
PT (1) PT2834244T (enExample)
SG (2) SG11201404522VA (enExample)
SI (1) SI2834244T1 (enExample)
TW (2) TWI586378B (enExample)
UA (1) UA115544C2 (enExample)
WO (2) WO2013136076A1 (enExample)
ZA (2) ZA201407374B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
AU2013234081B2 (en) 2012-03-13 2017-02-02 Respivert Limited Crystalline PI3 kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6434416B2 (ja) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113620958A (zh) 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
KR20170082490A (ko) 2014-07-04 2017-07-14 루핀 리미티드 Pi3k 억제제로서 퀴놀리지논 유도체
WO2016005443A1 (en) * 2014-07-09 2016-01-14 Arven Ilac Sanayi Ve Ticaret A.S. A process for the preparation of formulations for inhalation
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
PH12018500554B1 (en) 2015-09-14 2024-01-24 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
SG10202010192YA (en) 2016-04-15 2020-11-27 Chia Tai Tianqing Pharmaceutical Group Co Ltd Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1999028979A2 (en) 1997-12-02 1999-06-10 Alcatel Usa Sourcing, L.P. Digital phone system
ES2298323T3 (es) 1998-11-13 2008-05-16 Jagotec Ag Inhalador de polvo seco multidosis con reserva de polvo.
EP1140938B1 (en) 1999-01-11 2003-08-27 Princeton University High affinity inhibitors for target validation and uses thereof
DK1158958T3 (da) 1999-03-05 2007-10-08 Chiesi Farma Spa Forbedret pulverformulering til inhalering
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2003006628A2 (en) 2001-07-13 2003-01-23 Virtual Drug Development, Inc. Nad synthetase inhibitors and uses thereof
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2004037176A2 (en) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
CA2517888C (en) 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
EP1625165A2 (en) 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
EP1643973A1 (en) 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
WO2005012221A1 (ja) 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. ジフェニルエーテル化合物、その製造方法および用途
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
WO2005067901A2 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
EP1750714A1 (en) 2004-05-13 2007-02-14 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
ES2607804T3 (es) * 2004-05-13 2017-04-04 Icos Corporation Quinazolinones como inhibidores de la fosfatidilinositol humana 3-quinasa delta
JP2008500338A (ja) 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
CN101123968A (zh) 2004-06-04 2008-02-13 艾科斯有限公司 肥大细胞病的治疗方法
PE20060598A1 (es) 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
EP1885356A2 (en) 2005-02-17 2008-02-13 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
CN101506211B (zh) 2006-04-04 2013-05-22 加利福尼亚大学董事会 激酶拮抗剂
KR20090027218A (ko) 2006-05-24 2009-03-16 바이엘 쉐링 파마 악티엔게젤샤프트 면역원성이 감소된, 고친화도 인간 및 인간화된 항-α5β1 인테그린 작용 블로킹 항체
KR20090031544A (ko) 2006-06-29 2009-03-26 쉐링 코포레이션 치환된 비사이클릭 및 트리사이클릭 트롬빈 수용체 길항제
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
WO2008058402A1 (en) 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
US20100305113A1 (en) * 2007-05-09 2010-12-02 Hans-Georg Capraro Substituted Imidazopyridazines as Lipid Kinase Inhibitors
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
KR101653842B1 (ko) 2008-01-04 2016-09-02 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
CA2745280A1 (en) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
EP2379505A4 (en) 2008-12-05 2012-10-17 Designmedix Inc CHLOROQUINES MODIFIED BY A MONOCYCLIC GROUP OR A FUSED CYCLE GROUP
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
RU2012104214A (ru) 2009-08-05 2013-09-10 Верситек Лимитед Противовирусные соединения и способы их получения и применения
GB0918249D0 (en) * 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CN201676365U (zh) 2010-03-29 2010-12-22 山东京卫制药有限公司 带有语音提示的给药吸入装置
CN201692450U (zh) 2010-06-22 2011-01-05 于清 用于药物输送的高效干粉吸入器
ES2546422T5 (es) 2010-08-31 2023-01-20 Glaxosmithkline Ip Dev Ltd Productos medicinales de inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos
PL2621494T3 (pl) 2010-09-30 2019-04-30 Chiesi Farm Spa Zastosowanie stearynianu magnezu w preparatach w postaci suchego proszku do inhalacji
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CN202154919U (zh) 2011-05-03 2012-03-07 王晓明 一种防交叉感染雾化吸入装置
AU2013234081B2 (en) 2012-03-13 2017-02-02 Respivert Limited Crystalline PI3 kinase inhibitors

Also Published As

Publication number Publication date
ZA201407374B (en) 2016-10-26
UA115544C2 (uk) 2017-11-27
NI201400101A (es) 2016-11-30
ZA201407373B (en) 2016-10-26
CA2864643A1 (en) 2013-09-19
GT201400182A (es) 2015-09-17
TW201350139A (zh) 2013-12-16
HK1203812A1 (en) 2015-11-06
WO2013136075A1 (en) 2013-09-19
LT2834244T (lt) 2016-11-10
US9642799B2 (en) 2017-05-09
CN104302650B (zh) 2017-07-18
SI2834244T1 (sl) 2016-12-30
HUE029420T2 (en) 2017-02-28
AU2013234081A1 (en) 2014-08-21
CN104302650A (zh) 2015-01-21
EA023715B1 (ru) 2016-07-29
JP2018008992A (ja) 2018-01-18
JP6189874B2 (ja) 2017-08-30
CR20140416A (es) 2014-10-31
WO2013136076A1 (en) 2013-09-19
JP2015509972A (ja) 2015-04-02
CA2864652A1 (en) 2013-09-19
EA201491675A1 (ru) 2014-12-30
AU2013234080A1 (en) 2014-08-21
PE20142342A1 (es) 2015-01-16
MX2014010990A (es) 2014-10-13
DK2834244T3 (en) 2016-11-28
ES2650791T3 (es) 2018-01-22
CO7051030A2 (es) 2014-09-10
ES2600705T3 (es) 2017-02-10
TWI586378B (zh) 2017-06-11
CO7061079A2 (es) 2014-09-19
EA201491674A1 (ru) 2014-12-30
NZ627963A (en) 2015-08-28
EP2825202A1 (en) 2015-01-21
TW201400484A (zh) 2014-01-01
KR20140131971A (ko) 2014-11-14
AU2013234081B2 (en) 2017-02-02
CR20140417A (es) 2014-10-31
PH12014501713A1 (en) 2014-10-13
SG11201404519UA (en) 2014-10-30
CY1118565T1 (el) 2017-07-12
EA025465B1 (ru) 2016-12-30
PL2834244T3 (pl) 2017-01-31
CN104284679B (zh) 2017-08-04
CL2014002386A1 (es) 2015-02-27
IN2014MN02000A (enExample) 2015-08-14
PH12014501922A1 (en) 2014-11-24
SG11201404522VA (en) 2014-10-30
EP2834244A1 (en) 2015-02-11
US20150105408A1 (en) 2015-04-16
GT201400183A (es) 2015-07-08
ECSP14018142A (es) 2015-06-30
MY171125A (en) 2019-09-26
IN2014MN01998A (enExample) 2015-08-14
US20150099768A1 (en) 2015-04-09
MX355299B (es) 2018-04-11
MX2014010991A (es) 2014-10-13
HK1203487A1 (zh) 2015-10-30
NZ628072A (en) 2015-08-28
NI201400100A (es) 2015-01-12
US20170239256A1 (en) 2017-08-24
PT2834244T (pt) 2016-11-03
ECSP14018630A (es) 2015-09-30
PE20141964A1 (es) 2014-12-01
JP2015509973A (ja) 2015-04-02
MX357170B (es) 2018-06-27
AU2013234080B2 (en) 2016-12-22
EP2834244B1 (en) 2016-08-10
IL233883A0 (en) 2014-09-30
CN104284679A (zh) 2015-01-14
HRP20161383T1 (hr) 2016-12-02
EP2825202B1 (en) 2017-09-06
TWI617561B (zh) 2018-03-11
CL2014002385A1 (es) 2015-01-09
KR20140141596A (ko) 2014-12-10

Similar Documents

Publication Publication Date Title
IL233886A (en) Solid anhydrous crystalline form of 6 - (2 - ((4-amino-3- (3-hydroxyphenyl) -1h- pyrazolo [3,4- d] pyrimidine-1-yl) methyl) -3- (2-chlorobenzyl) -4-oxo-3,4 dihydroquinazoline-5-yl) n, n-bis (2-methoxyethyl) hex-5-inamide
IL257410A (en) Pyrazolo [1, 5 – a ] pyrimidines as antiviral agents
IL266285B (en) Methods for the production of thiano [d – 3,2] pyrimidine compounds
PT2794611T (pt) Pirazolo[1,5-a]pirimidinas como agentes antivirais
ZA201307839B (en) Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors
EP2751112A4 (en) SUBSTITUTED PYRAZOLO [3,4-D] PYRIMIDINE AND ITS USE
IL225580B (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[3,2-d] pyrimidine-6-carboxylic acid dimethylamide and processes for their preparation
CO6801740A2 (es) Inhibidores de quinasa relacionados con pirrolo[2,3-d]pirimidina tropomiosina
CL2013001057A1 (es) Un compuesto 6-(2-((4-amino-3-(3-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)metil)-3-(2-clorobencil)-4-oxo-3,4-dihidroquinazolin-5-il)-n,n-bis(2-metoxietil)hex-5-inamida, inhibidores de pi3 cinasa; compuesto intermediario; composicion farmaceutica, util para tratar o prevenir epoc, rinitis, artritis reumatoidea y carcinomas.
AP3902A (en) Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
IL227526A0 (en) Derivatives of 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidine-4-one and their use as a9pde inhibitors
SI2935274T1 (sl) 3-okso-2,3,5,8-tetrahidro-(1,2,4)triazolo(4,3-a)pirimidinski derivati za zdravljenje bolezni dihal
SG11201505520WA (en) 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORS
EP2739627A4 (en) 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
PL2694513T3 (pl) Pochodne pirazolopirymidynowe
EP2323663A4 (en) 4-amino-3- (imidazolyl) -PYRAZOLO- [3,4-D] pyrimidines
ZA201405167B (en) Water-soluble granule formulation of 2,4-d salt and preparation method thereof
EP2523552A4 (en) PYRAZOLO- [1,5-A] PYRIMIDINE AS MARK HEMMER
IL231934A (en) 4-Amino-3-Phenylamino-6-Phenylpyrazolo (4,3-d) Pyramidine derivatives, their production and use as active antiviral substances
IL237677B (en) Process for preparing 2-amino-8,5-dimethoxy[4,2,1]triazolo[5,1-c]pyrimidine from 4-chloro-5,2-dimethoxypyrimidine

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees